I-Mab (IMAB)
NASDAQ: IMAB · Real-Time Price · USD
0.8000
-0.0413 (-4.91%)
Mar 31, 2025, 12:55 PM EDT - Market open
I-Mab Revenue
I-Mab had revenue of $569.46K in the twelve months ending September 30, 2024, down -100.50% year-over-year. In the year 2023, I-Mab had annual revenue of $27.64M, down -112.48%.
Revenue (ttm)
$569.46K
Revenue Growth
-100.50%
P/S Ratio
120.62
Revenue / Employee
$2,588
Employees
220
Market Cap
65.15M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IMAB News
- 9 days ago - I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 24 days ago - I-Mab Announces Accelerated Givastomig Phase 1b Study Progress - GlobeNewsWire
- 5 weeks ago - I-Mab to Participate in Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member - PRNewsWire
- 3 months ago - I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program - PRNewsWire
- 4 months ago - I-Mab to Participate at the Piper Sandler Healthcare Conference - PRNewsWire
- 4 months ago - I-Mab Reports Third Quarter 2024 Results - PRNewsWire